---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-138946"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:21:14.709060+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Verrica Q1 net loss narrows to $6.6M; raised $32.5M; YCANTH PDUFA July 23, 2023

## Summary
- Net loss of $6.6M ($0.15 GAAP EPS) vs $8.5M ($0.31) in Q1 2022; non-GAAP net loss $5.5M ($0.13).
- Cash and equivalents $60.0M as of March 31, 2023; management expects runway into Q1 2024.
- PDUFA goal date of July 23, 2023 for YCANTH (VP-102) for molluscum contagiosum; no FDA-approved therapy exists.
- Raised $32.5M gross proceeds in February 2023 underwritten offering to support pre-commercial activities and VP-315 trial.
- VP-315 advanced into Part 2 of Phase 2 study for basal cell carcinoma; Part 3 expected to start first half 2024.

## SEC filing metadata
- accession: 0001193125-23-138946
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312523138946/0001193125-23-138946-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312523138946/d429426d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-138946
- JSON: https://secwatch.observer/filing/0001193125-23-138946.json
- Plain text: https://secwatch.observer/filing/0001193125-23-138946.txt

## Key facts
- Earnings Releases
  Verrica Pharmaceuticals Inc. reported the first quarter ended March 31, 2023 results: revenue $37,000, net income $6.6 million, EPS $0.15 per share.
  - Period: the first quarter ended March 31, 2023
  - Revenue: $37,000
  - Net income: $6.6 million
  - EPS: $0.15 per share
  - Result: reported results
  source text: million underwritten offering of common stock and pre-funded warrants. Financial Results First Quarter 2023 Financial Results • Verrica recognized collaboration revenues of $37,000 in the first quarter of 2023 compared to $0.4 million for the same period in 2022 related to the Collaboration and License Agreement with Torii Pharmaceutical Col, Ltd (“Torii”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1660334/000119312523138946/0001193125-23-138946-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.